SUMO1 emerges as a potential biomarker of susceptibility to PTSD, PTSD duration, and PTSD remission, as well as an indicator of the effectiveness of therapies aimed at restoring neuroplasticity. Here, SUMO1 is linked to post-traumatic stress disorder.